On this page
Humanin Quick Reference (10 mg Vial)
- Vial contents
- 10 mg Humanin
- Final volume
- 3 mL
- Concentration
- 3.33 mg/mL
- One U-100 unit
- 33.33 mcg in 0.01 mL
Humanin Dosage Chart
Dosage & Reconstitution Guide
Community-Reported Use Calculations (3.0 mL = 3.333 mg/mL)
Community-Reported Use Calculations (3.0 mL = 3.333 mg/mL)
| Research Period | Amount per Administration | U-100 Units (mL) |
|---|---|---|
| 8 weeks | 1 mg | 30 units (0.30 mL) |
| 8 weeks | 2 mg | 60 units (0.60 mL) |
| 8 weeks | 3 mg | 90 units (0.90 mL) |
Frequency: Twice weekly in the recurring community descriptions selected for this worked example. Each row is independent, not a titration schedule.
Research reference only: The 1–3 mg, twice-weekly, eight-week patterns are nonclinical community descriptions. Reports vary materially, and no academic humanin trial establishes these schedule numbers. The academic references support identity, mechanism, model findings, and evidence limits—not the charted regimen.
Reconstitution Steps
- Clean the vial stopper and diluent stopper with alcohol; allow both to dry.
- Draw exactly 3.0 mL of bacteriostatic water with a new sterile syringe, then inject it slowly down the inside wall of the vial.
- Gently swirl or roll until dissolved. Do not shake.
- Label the vial with the compound, concentration, and reconstitution date. Refrigerate at 2–8 °C (36–46 °F) and protect from light.
Storage note: No compound-specific post-reconstitution stability or discard period has been established for this worked research-vial preparation. Follow the lot-specific product documentation for any shorter limit.
Supplies Needed
Choose one eight-week calculation row. Do not add the rows together.
- Peptide Vials (Humanin, 10 mg each):
- 8 weeks at 1 mg twice weekly: 2 vials
- 8 weeks at 2 mg twice weekly: 4 vials
- 8 weeks at 3 mg twice weekly: 5 vials
- Insulin Syringes (U-100):
- 16 calculated administrations: 16 syringes
- Bacteriostatic Water (10 mL bottles):
- 2-vial calculation: 6 mL
- 4-vial calculation: 12 mL
- 5-vial calculation: 15 mL
- Alcohol Swabs:
- 16 calculated administrations at 2 swabs each: 32 swabs
Sharps safety: Place used needles and syringes immediately in an approved sharps container.
Humanin Vial and Research Context
- Reconstitute: Add 3.0 mL bacteriostatic water for a worked concentration of 3.333 mg/mL.
- Vial contents: 10 mg Humanin.
- U-100 conversion: 1 unit = 0.01 mL = 33.333 mcg.
- Storage: Refrigerate at 2–8 °C and protect from light.
Published Humanin research is largely mechanistic, observational, cellular, or preclinical.[1][2][3][5] The rows below are transparent community-reported calculations and must not be presented as clinical recommendations.
Humanin Research Context
Humanin is a mitochondrial-derived peptide first identified through cytoprotection research.[1] Subsequent reviews discuss mitochondrial signaling, stress responses, metabolism, cardiovascular biology, and aging-related models.[2][3][6][7][9] These publications do not establish a controlled human dosing regimen.
Human tissue, cell, biomarker, and animal studies should not be conflated with human administration trials.[4][5][8] The primary chart is therefore labeled Community-reported use, and its academic citations support only identity, mechanism, and evidence limits.
10 mg Vial Calculation Notes
- 10 mg divided by 3.0 mL equals 3.333 mg/mL.
- One U-100 unit equals 0.01 mL or 33.333 mcg.
- 1, 2, and 3 mg equal 30, 60, and 90 units, respectively.
- The eight-week period and twice-weekly frequency are calculation choices based on recurring community descriptions, not a validated course.
Native Humanin and HNG Are Not Interchangeable
Several preclinical papers investigate HNG, an S14G humanin analog, rather than native humanin.[10][12] Reviews of cardiac-apoptosis signaling and other delivery studies also use analogs or disease-specific model systems.[11][14] Those results cannot be used to assign the same mass, potency, pharmacokinetics, or clinical effect to native humanin.
Evidence Limits and Safety
No controlled human administration study identified for this review establishes a native-humanin dose, route, frequency, duration, efficacy outcome, or safety profile. Cell and tissue findings in vascular and retinal models remain preclinical.[5][13] The public references intentionally exclude clinics, forums, and competing peptide sellers.
References
- 1Hashimoto et al., 2001, PMID 11371646 – Original discovery of humanin as a mitochondrial-derived peptide with cytoprotective activity in cell models.
- 2Yen et al., 2020, PMID 33130077 – Review of humanin biology, mitochondrial signaling, and disease-model research.
- 3Yen et al., 2020, PMID 32575074 – Study associating circulating humanin levels with healthspan and lifespan across species.
- 4Klein et al., 2017, PMID 29187525 – Study of humanin and chaperone-mediated autophagy in cellular models.
- 5Bachar et al., 2010, PMID 20562421 – Humanin expression and cytoprotective effects in human vascular tissue and cultured cells.
- 6Cai et al., 2020, PMID 32680738 – Review of humanin and other mitochondrial-derived peptides in cardiovascular research.
- 7Reynolds et al., 2023, PMID 38008175 – Review of mitochondrial-derived peptides in cardiovascular physiology and disease.
- 8Kim et al., 2025, PMID 41303353 – Case-control study of circulating humanin in Alzheimer disease and mild cognitive impairment.
- 9Sreekumar et al., 2021, PMID 34177809 – Review of humanin, oxidative stress, and age-related disease models.
- 10Muzumdar et al., 2010, PMID 20197306 – Mouse study of humanin analog HNG and insulin sensitivity; HNG is not native humanin.
- 11Thummasorn et al., 2016, PMID 26667157 – Review of humanin-family signaling in cardiac apoptosis research.
- 12Lee et al., 2021, PMID 34506248 – Preclinical study of the humanin analog HNG in cardiac dysfunction.
- 13Sreekumar et al., 2022, PMID 35576057 – Cell study of humanin-related protection in an age-related macular degeneration model.
- 14Gong et al., 2023, PMID 37351170 – Preclinical intranasal delivery study involving a humanin analog in a Parkinson disease model.